Neuberger Berman Group LLC Increases Position in Moderna, Inc. (NASDAQ:MRNA)

Key Points

• Neuberger Berman Group LLC increased its stake in Moderna, Inc. by 39.0%, acquiring an additional 17,309 shares, bringing its total holdings to 61,666 shares worth approximately $1.75 million.
• Analysts have set varying price targets for Moderna, with a consensus price target of $43.59 and a predominance of hold ratings from multiple firms.
• Moderna reported a negative EPS of ($2.13) for the last quarter, surpassing analyst expectations, but revenues declined by 41.1% compared to the previous year.

Neuberger Berman Group LLC increased its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 39.0% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 61,666 shares of the company's stock after buying an additional 17,309 shares during the quarter. Neuberger Berman Group LLC's holdings in Moderna were worth $1,748,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MRNA. S Bank Fund Management Ltd bought a new stake in shares of Moderna in the 1st quarter worth approximately $25,000. Costello Asset Management INC acquired a new position in shares of Moderna during the 1st quarter valued at $30,000. Sentry Investment Management LLC acquired a new position in shares of Moderna during the 1st quarter valued at $31,000. Deseret Mutual Benefit Administrators increased its position in shares of Moderna by 53.3% during the 1st quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company's stock valued at $32,000 after purchasing an additional 392 shares during the period. Finally, Itau Unibanco Holding S.A. grew its holdings in shares of Moderna by 51.2% in the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock worth $42,000 after acquiring an additional 343 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently commented on MRNA. Royal Bank Of Canada decreased their target price on Moderna from $32.00 to $28.00 and set a "sector perform" rating for the company in a research report on Friday, May 2nd. Citigroup initiated coverage on Moderna in a report on Friday, August 1st. They set a "neutral" rating and a $40.00 target price on the stock. Evercore ISI set a $32.00 price objective on Moderna in a research note on Friday, August 1st. Barclays lowered their price target on Moderna from $40.00 to $31.00 and set an "equal weight" rating on the stock in a research note on Monday, August 4th. Finally, Cowen assumed coverage on Moderna in a research note on Sunday, July 13th. They set a "hold" rating on the stock. Four analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $43.59.

Moderna Trading Up 5.0%

Shares of MRNA stock traded up $1.33 during trading on Friday, reaching $28.02. 9,362,516 shares of the company's stock traded hands, compared to its average volume of 8,647,570. Moderna, Inc. has a 1 year low of $23.15 and a 1 year high of $91.99. The company has a market capitalization of $10.90 billion, a P/E ratio of -3.72 and a beta of 1.83. The firm's 50-day moving average is $29.20 and its 200 day moving average is $29.35.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The company reported ($2.13) EPS for the quarter, topping analysts' consensus estimates of ($2.99) by $0.86. The firm had revenue of $142.00 million for the quarter, compared to analyst estimates of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The business's revenue for the quarter was down 41.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($3.33) EPS. As a group, sell-side analysts predict that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.